Introduction
============

It was estimated that there were \~14 million new cancer cases in 2012 and the number is expected to rise to 22 million in the next two decades ([@b1-mmr-16-02-1927]). Cancer-associated mortality, meanwhile, was \~8.2 million in 2012 and is predicted to rise to 13 million by 2032 ([@b1-mmr-16-02-1927]). Thus, an improved understanding of the pathogenic mechanisms of cancer is of great importance. At present, it is widely accepted that cancer is a multifactorial and complex disease resulting from interaction between environmental and genetic factors ([@b2-mmr-16-02-1927]).

Single nucleotide polymorphisms (SNPs) are frequently occurring variations in the human genome, and have been extensively investigated in genetic studies of cancer. Recent studies have demonstrated that SNPs of multiple genes may have an important role in cancer occurrence and progression ([@b3-mmr-16-02-1927]). In addition, numerous publications have reported that cytokine gene polymorphisms may affect inflammatory-related pathways, and influence susceptibility to different types of cancer ([@b4-mmr-16-02-1927],[@b5-mmr-16-02-1927]). Interleukin-4 (IL-4) is a potent regulator of antitumor immune responses with both tumor-promoting and tumor-inhibiting properties, since it has both immunosuppressive and anti-angiogenic functions ([@b6-mmr-16-02-1927]--[@b9-mmr-16-02-1927]). Consequently, certain genetic polymorphisms of IL-4 gene are considered as good candidates for cancer susceptibility prediction. To date, several studies have aimed to assess the potential association of IL-4 polymorphisms rs2243250 \[-590C to T, 5′untranslated region (UTR)\], rs2070874 (−34C to T, 5′ UTR) and rs79071878 (intron-3, 70 bp variable number tandem repeat, VNTR) with cancer risk, but the results remain inconsistent. Therefore, a meta-analysis was performed in the present study in order to better elucidate the roles of IL-4 gene polymorphisms in the occurrence and progression of cancer.

Materials and methods
=====================

### Study identification and selection

Potentially relevant articles were independently identified by three investigators from the Medline (<http://www.medline.com/>), PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), Embase (<https://www.embase.com>) and China National Knowledge Infrastructure databases (<http://www.cnki.net/>). The searching terms were as follows: (Interleukin-4 OR IL-4 OR Interleukin 4 OR IL 4) AND (polymorphism OR variant OR genotype OR allele) AND (cancer OR tumor OR carcinoma OR neoplasm). In addition, the reference lists of retrieved articles were searched manually for additional eligible studies. Among studies with overlapping data published by the same authors, only the most recent and complete study was included in the present meta-analysis.

### Inclusion and exclusion criteria

The following inclusion criteria were used to select eligible articles: i) Case-control study of cancer cases and healthy controls; ii) investigate the relationship between IL-4 gene polymorphisms and cancer risk; iii) provide both genotype and allele distributions inpatients and controls; iv) full text in English or Chinese available. Articles were excluded if: i) The study was duplicated; ii) the analyses were based on linkage considerations; iii) the report was not original (reviews or meta-analyses).

### Data extraction and quality assessment

The following information was extracted from all included studies independently by two authors: i) Name of the first author; ii) year of publication; iii) country in which the study was conducted; iv) ethnicity of study population; v) cancer type; vi) allele and genotype frequencies of IL-4 gene polymorphisms in cases and controls; vii) P-value of Hardy-Weinberg equilibrium (HWE) in the control group. The Newcastle-Ottawa quality assessment scale was used to evaluate the quality of all included studies ([@b10-mmr-16-02-1927]). This rating scale has a score range of 0 to 9, and studies with scores \>7 were assumed to be of high quality. Two reviewers performed data extraction and quality assessment independently. When necessary, the reviewers wrote to the corresponding authors for extra information or raw data. Disagreements between reviewers were resolved by discussion until a consensus was achieved. The final results were reviewed by a senior reviewer.

### Statistical analysis

All statistical analyses were performed with Review Manage version 5.3 (Cochrane, London, United Kingdom). HWE in the control group was estimated using the χ^2^test. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the strength of the associations between IL-4 gene polymorphisms and cancer susceptibility. In addition, heterogeneity among studies was assessed using the Q test and I^2^ statistics. When the probability value (P-value) of Q test was \<0.1 or I^2^ was \>50%, inter-study heterogeneity was considered to be significant, and the random-effects model (REM) was employed for analyses. Otherwise, the fixed-effect model (FEM) was applied for analyses. First, associations based on all study subjects were analyzed, and then subgroup analyses by cancer type and ethnicity were performed to obtain the cancer type-specific effects and the ethnic-specific effects of IL-4 polymorphisms. Sensitivity analyses were conducted by sequentially omitting one individual study each time to assess the stability of the results. Furthermore, the possible publication bias was evaluated by using funnel plots (data not shown).

Results
=======

### Characteristics of eligible studies

The literature search identified 1,237 eligible articles. After reading titles and abstracts, a total of 94 articles were selected for further evaluation. Amongst these, 51 articles were excluded based on the inclusion and exclusion criteria, as described in the Methods. Finally, 43 articles ([@b11-mmr-16-02-1927]--[@b53-mmr-16-02-1927]), 33 studies focusing on polymorphism rs2243250, 11 studies onrs2070874, and 10 studies on rs79071878, were included in the meta-analysis. The majority of the articles were published in English, except for three that were published in Chinese. A schematic of the selection process is illustrated in [Fig. 1](#f1-mmr-16-02-1927){ref-type="fig"}.

### IL-4 rs2243250 polymorphism and the risk of cancer

For IL-4 rs2243250 polymorphism, a total of 33 studies including 10,873 cancer cases and 14,328 normal controls were investigated. Deviations from HWE were observed in 9 studies, while the other 24 studies were in accordance with HWE ([Table I](#tI-mmr-16-02-1927){ref-type="table"}). As illustrated in [Fig. 2](#f2-mmr-16-02-1927){ref-type="fig"}, the meta-analysis identified a significant association between IL-4 rs2243250 polymorphism and cancer risk (CT vs. CC/TT: P=0.008, OR=0.88, 95% CI 0.80--0.97) with an overt heterogeneity across studies (I2=56%). Subgroup analyses were then performed based on cancer type ([Table II](#tII-mmr-16-02-1927){ref-type="table"}). The results suggested that the IL-4 rs2243250 polymorphism was significantly associated with an increased risk of gastric cancer (CT vs. TT: P=0.004, OR=0.75, 95% CI 0.61--0.91; CT vs. CC/TT: P=0.002, OR=0.77, 95% CI 0.66--0.91; and C vs. T: P=0.04, OR=1.15, 95% CI 1.01--1.32), breast cancer (CC vs. CT: P=0.05, OR=1.21, 95% CI 1.00--1.46; TT vs. CC: P=0.04, OR=0.56, 95% CI 0.33--0.97; CC vs. CT/TT: P=0.02, OR=1.25, 95% CI 1.04--1.51; and C vs. T: P=0.007, OR=1.25, 95% CI 1.06--1.47), lung cancer (CT vs. CC/TT: P=0.02, OR=0.84, 95% CI 0.75--0.97), prostate cancer (CT vs. TT: P=0.004, OR=1.48, 95% CI 1.14--1.92;TT vs. CC: P=0.0009, OR=0.48, 95% CI 0.31--0.74; CT vs. CC/TT: P=0.02, OR=1.33, 95% CI 1.05--1.69; and TT vs. CC/CT: P=0.0004, OR=0.64, 95% CI 0.50--0.82) and leukemia (CC vs. CT: P=0.005, OR=5.35, 95% CI 1.64--17.47;CC vs. CT/TT: P=0.01, OR=4.67, 95% CI 1.42--15.31; and CT vs. CC/TT: P=0.005, OR=0.19, 95% CI 0.06--0.61). Studies in each cancer subgroup were homogenous. No significant association between IL-4 rs2243250 polymorphism and cancer risk was identified for oral carcinoma, colorectal cancer, skin cancer, hepatocellular carcinoma, lymphoma, bladder cancer, brain tumor, testicular tumor, renal cell carcinoma, and brain tumor ([Table II](#tII-mmr-16-02-1927){ref-type="table"}). Subgroup analyses were also conducted by ethnicity. As illustrated in [Table II](#tII-mmr-16-02-1927){ref-type="table"}, a significant association between IL-4 rs2243250 polymorphism and cancer risk was identified in both Caucasian (CT vs. TT: P=0.03, OR=0.82, 95% CI 0.68--0.98, I2=46%; CT vs. CC/TT: P=0.02, OR=0.79, 95% CI 0.66--0.96, I2=64%) and Asian populations (CT vs. CC/TT: P=0.006, OR=0.89, 95% CI 0.82--0.97, I2=36%).

### IL-4 rs2070874 polymorphism and the risk of cancer

For IL-4 rs2070874 polymorphism, 11 studies involving 3,970 patients and 5,686 controls were included. All relevant studies were in agreement with HWE ([Table III](#tIII-mmr-16-02-1927){ref-type="table"}). Inter-study heterogeneity was obvious in all comparisons and thus REMs were used for analyses. No significant association between IL-4 rs2070874 polymorphism and cancer risk was observed in all genetic models ([Fig. 3](#f3-mmr-16-02-1927){ref-type="fig"}). Further stratification analyses by cancer type revealed a significant association with leukemia (CC vs. CT: P=0.05, OR=3.27, 95% CI1.02--10.45; CT vs. TT: P=0.02, OR=0.03, 95% CI 0.00--0.57; and CT vs. CC/TT: P=0.02, OR=0.24, 95% CI 0.08--0.77), and oral carcinoma (CT vs. TT: P=0.02, OR=1.93, 95% CI1.13--3.29; CT vs. CC/TT: P=0.05, OR=1.67, 95% CI 1.00--2.77; TT vs. CC/CT: P=0.006, OR=0.50, 95% CI 0.31--0.82; and C vs. T: P=0.007, OR=1.69, 95% CI 1.16--2.48) ([Table II](#tII-mmr-16-02-1927){ref-type="table"}). Nevertheless, no association was observed between rs2070874 polymorphism and other tumor types ([Table III](#tIII-mmr-16-02-1927){ref-type="table"}). In the subgroup analyses by ethnicity, a significant association was found in Asian populations (CT vs. CC/TT: P=0.03, OR=0.85, 95% CI 0.73--0.98), but not in Caucasian populations ([Table IV](#tIV-mmr-16-02-1927){ref-type="table"}).

### IL-4 rs79071878 polymorphism and the risk of cancer

A total of 10 studies with 1,896 patients and 2,526 controls were involved in the present analyses for IL-4 rs79071878 polymorphism and cancer risk. HWE test revealed that only one study deviated from HWE ([Table V](#tV-mmr-16-02-1927){ref-type="table"}). IL-4 VNTR is a 70 bp repeat. Alleles of two and three repeats were designated as repeat 1 (RP1) and repeat 2 (RP2), respectively, and genotypes of RP1/RP1, RP1/RP2 and RP2/RP2 were designated as RP1.1, RP1.2 and RP2.2, respectively. For RP1.2 vs. RP2.2, RP2.2 vs. RP1.1 and RP2.2 vs. RP1.1/RP1.2, FEMs were selected for analyses since only mild inter-study heterogeneity was observed. In contrast, for RP1.1 vs. RP1.2, RP1.1 vs. RP1.2/RP2.2, RP1.2 vs. RP1.1/RP2.2 and RP1 vs. RP2, REMs were used because heterogeneity between studies was significant. The results demonstrated an apparent correlation between IL-4 rs79071878 polymorphism and cancer risk (RP1.2 vs. RP2.2: P=0.008, OR=1.40, 95% CI 1.09--1.79; RP2.2 vs. RP1.1: P=0.006, OR=0.62, 95% CI0.44--0.87, RP2.2 vs. RP1.1/RP1.2: P=0.002, OR=0.69, 95% CI 0.55--0.88; and RP1.1 vs. RP2.2: P=0.05, OR=1.26, 95% CI 1.00--1.58; [Fig. 4](#f4-mmr-16-02-1927){ref-type="fig"}). Further analyses by cancer type subgroup revealed that the rs79071878 polymorphism was associated with an increased risk of bladder cancer (RP1.1 vs. RP1.2: P\<0.0001, OR=3.78, 95% CI 2.03--7.05; RP2.2 vs. RP1.1: P=0.002, OR=0.07, 95% CI 0.01--0.38; RP1.1 vs. RP1.2/RP2.2: P\<0.0001, OR=4.28, 95% CI 2.35--7.81; and RP2.2 vs. RP1.1/RP1.2: P=0.004, OR=0.42, 95% CI 0.24--0.76) and breast cancer (RP1.2 vs. RP2.2: P=0.05, OR=1.70, 95% CI 1.00--2.88) ([Table VI](#tVI-mmr-16-02-1927){ref-type="table"}). However, no significant association was observed in other types of cancer. Furthermore, stratified analysis by ethnicity yielded a significant association for the IL-4 rs79071878 polymorphism with cancer risk in the Asian ethnicity (RP1.2 vs. RP2.2: P=0.03, OR=1.38, 95% CI 1.04--1.83; and RP2.2 vs. RP1.1/RP1.2: P=0.01, OR=0.71, 95% CI 0.54--0.93). However, no evidence for any associations between IL-4 rs79071878 polymorphism and cancer risk was detected in the Caucasian ethnicity ([Table VI](#tVI-mmr-16-02-1927){ref-type="table"}).

### Sensitivity analysis and publication bias

Sensitivity analyses were performed by removing one individual study from the analysis at a time. For IL-4 rs2243250 polymorphism, when the study of Chen *et al* ([@b22-mmr-16-02-1927]) was omitted, the comparison in CT vs. TT yielded positive result (P=0.03, OR=0.88, 95% CI 0.79--0.98). For IL-4 rs2070874 and rs79071878 polymorphisms, however, removing individual studies did not impact the overall results. Publication bias was evaluated with funnel plots, and visual inspection of the funnel plots for all investigated polymorphisms indicated that there was no significant publication bias in the present meta-analysis.

Discussion
==========

Cancer is a major public health problem with extremely high morbidity and mortality. Certain cytokine gene polymorphisms may serve crucial roles in cancer pathogenesis. Among these, IL-4 rs2243250, rs2070874 and rs79071878 polymorphisms are three intensively studied variants. Previous studies have demonstrated that the T allele of IL-4 rs2243250 and rs2070874 polymorphisms can increase binding of nuclear transcription factors to the promoter region of the IL-4 gene, and thus lead to increased transcription of IL-4 ([@b32-mmr-16-02-1927],[@b43-mmr-16-02-1927]). In addition, the rs79071878 polymorphism may also affect the transcription activity of IL-4 ([@b54-mmr-16-02-1927]). However, despite the identifications of these potential mechanisms, the results concerning the association of IL-4 gene polymorphisms and cancer risk remain controversial. Thus, in order to clarify this association, a meta-analysis was performed in the present study to estimate the correlation between IL-4 gene polymorphisms (rs2243250, rs2070874 and rs79071878) and cancer susceptibility.

For IL-4 rs2243250 polymorphism, the present data suggested that this polymorphism was significantly associated with cancer risk. In subgroup analyses by cancer type, rs2243250 was demonstrated to be associated with a higher risk of gastric cancer and breast cancer. The CT/TT genotype carriers were at a lower risk of developing gastric cancer or breast cancer compared with individuals with the CC genotype. Furthermore, the CT genotype was demonstrated to be associated with an increased risk of prostate cancer compared with the CC/TT genotypes. These results suggested that this polymorphism may serve different roles in different types of malignancies. Further subgroup analysis by ethnicity revealed that the IL-4 rs2243250 polymorphism was correlated with an increased cancer risk in both Asian and Caucasian populations. The overall analysis for the IL-4 rs2070874 polymorphism yielded no significant association with general cancer risk. In the cancer-type subgroup analysis, a significant association of IL-4 rs2070874 polymorphism with leukemia and oral carcinoma was identified, with patients carrying the CT genotype or the C allele being more likely to develop oral carcinoma. By contrast, for leukemia the CT genotype carriers were at a lower risk of developing leukemia. It is worth noting that these results should be interpreted with caution, since our estimations regarding leukemia and oral carcinoma were based on one single study. Additionally, in ethnicity sub-analysis, the results indicated a significant association with cancer susceptibility among Asian populations under the recessive genetic model. Finally, the IL-4 rs79071878 polymorphism was overtly associated with a higher risk of cancer under the allelic model. The results of subgroup analyses indicated that IL-4 rs79071878 polymorphism was significantly associated with bladder cancer and breast cancer in certain genetic models, and an association between IL-4 rs79071878 polymorphism and cancer susceptibility was only observed among Caucasians, but not Asians. Overall, from general and subgroup analyses, it can be concluded that IL-4 gene polymorphisms may be important in the pathogenesis of certain types of cancer, and their effects on cancer risk may be ethnic specific. Nevertheless, the amount of relevant studies is not sufficient to draw a safe conclusion, and further well-designed studies with larger patient sample size will be required in the future to validate the present results.

Heterogeneity is one of the most important issues when performing meta-analysis. In the present meta-analysis, heterogeneity between studies existed in almost all comparisons. Therefore, we attempted to detect the source of heterogeneity by dividing included studies into different subgroups according to cancer type and ethnicity. The heterogeneity was drastically decreased in most subgroups, suggesting that these two factors contribute to a significant portion of heterogeneity in the present meta-analysis.

When interpreting the results of the present meta-analysis, several limitations should be considered. Firstly, the numbers of relevant studies were limited, and studies regarding several particular types of cancer were extremely lacking. Secondly, although funnel plots did not reveal any publication bias, the possibility of publication bias cannot be completely eliminated, since only published studies were included. Thirdly, the present results were based on unadjusted estimates, while a more precise analysis should have been adjusted by other factors, including smoking, age, and environmental factors. Finally, the present analyses did not consider the possibility of gene-gene or SNP-SNP interactions or the possibility of linkage disequilibrium between polymorphisms. Taking all these limitations into consideration, the results reported by the current study should be interpreted with caution.

In summary, the present results suggest that the IL-4 rs2243250 and rs79071878 polymorphisms were associated with cancer susceptibility. Further subgroup analyses revealed that the effects of IL-4 gene polymorphisms on cancer risk may vary depending on the cancer type and the ethnicity. However, given that the present results were based on limited number of case-control studies, further multi-center studies with larger sample size from different populations are warranted to confirm our results.
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###### 

Characteristics of subjects included in the meta-analysis of interleukin-4 rs2243250 polymorphism and cancer risk.

                                                                                      Case   Control                                                                    
  ----------------------- ------------------ ----------- ---------------------------- ------ ------------ ----------- ------ ------------ ----------- ------------- --- -------------------------
  Amirzargar, 2005        Iran               Caucasian   Leukemia                     30     13/17/0      71.7/28.3   40     5/35/0       56.3/43.7   **\<0.001**   7   ([@b42-mmr-16-02-1927])
  Andrie, 2009            Greece             Caucasian   Lymphoma                     85     66/17/2      87.6/12.4   85     70/14/1      90.6/9.6    0.753         7   ([@b26-mmr-16-02-1927])
  Chang, 2015             Taiwan             Asian       Lung cancer                  358    247/95/16    82.3/17.7   716    439/218/59   76.5/23.5   **\<0.001**   7   ([@b35-mmr-16-02-1927])
  Chen, 2016              China              Asian       Prostate cancer              439    46/171/222   30.0/70.0   524    29/173/322   22.0/78.0   0.368         7   ([@b22-mmr-16-02-1927])
  Chu, 2012               China              Asian       Bladder cancer               816    39/264/513   21.0/79.0   1140   46/393/701   21.3/78.7   0.322         7   ([@b41-mmr-16-02-1927])
  Chu, 2012               China              Asian       Renal cell carcinoma         620    22/189/409   18.8/81.2   623    36/195/392   21.4/78.6   0.079         7   ([@b18-mmr-16-02-1927])
  Cozar, 2007             Spain              Caucasian   Renal cell carcinoma         127    93/30/4      85.0/15.0   174    123/47/4     84.2/15.8   0.844         7   ([@b19-mmr-16-02-1927])
  Cozar, 2007             Spain              Caucasian   Colorectal cancer            96     68/25/3      83.9/16.1   174    123/47/4     84.2/15.8   0.844         7   ([@b19-mmr-16-02-1927])
  Crusius, 2008           Netherlands        Caucasian   Gastric cancer               242    159/76/7     81.4/18.6   1154   824/305/25   84.6/15.4   0.603         7   ([@b11-mmr-16-02-1927])
  El-omar, 2003           Scotland           Mixed       Esophageal cancer            90     55/28/7      76.7/23.3   209    153/46/10    84.2/15.8   **0.013**     7   ([@b12-mmr-16-02-1927])
  El-omar, 2003           Scotland           Mixed       Gastric cancer               122    78/37/7      79.1/20.9   209    153/46/10    84.2/15.8   **0.013**     7   ([@b12-mmr-16-02-1927])
  Garcia-Gonzalez, 2007   Spain              Caucasian   Gastric cancer               404    283/107/14   83.3/16.7   404    267/123/14   81.3/18.7   0.971         8   ([@b13-mmr-16-02-1927])
  Gaur, 2011              India              Caucasian   Oral carcinoma               140    18/55/67     32.5/67.5   120    9/35/76      22.1/77.9   0.095         8   ([@b28-mmr-16-02-1927])
  Gu, 2014                China              Asian       Lung cancer                  500    22/157/321   20.1/79.9   500    15/161/324   19.1/80.9   0.348         7   ([@b34-mmr-16-02-1927])
  Howell, 2003            UK                 Caucasian   Skin cancer                  153    130/23/0     92.5/7.5    208    165/39/4     88.7/11.3   0.352         8   ([@b25-mmr-16-02-1927])
  Joshi, 2014             India              Caucasian   Breast cancer                163    120/39/4     85.6/14.4   224    144/72/8     80.4/19.6   0.786         8   ([@b20-mmr-16-02-1927])
  Lai, 2005               Taiwan             Asian       Gastric cancer               123    2/38/83      17.1/82.9   162    7/50/105     19.8/80.2   0.736         7   ([@b14-mmr-16-02-1927])
  Li, 2012                China              Asian       Lung cancer                  1072   54/280/738   18.1/81.9   1126   94/341/691   23.5/76.5   **\<0.001**   7   ([@b33-mmr-16-02-1927])
  Liang, 2010             China              Asian       Gastric cancer               238    10/53/175    15.3/84.7   112    6/28/78      17.9/82.1   0.118         7   ([@b17-mmr-16-02-1927])
  Lu, 2014                China              Asian       Hepatocellular cancer        154    4/39/111     15.3/84.7   170    4/51/115     17.4/82.6   0.055         7   ([@b31-mmr-16-02-1927])
  Monroy, 2011            USA                Mixed       Lymphoma                     100    69/27/4      82.5/17.5   100    67/24/9      79.0/21.0   **0.006**     7   ([@b27-mmr-16-02-1927])
  Olson, 2007             USA                Mixed       Prostate cancer              149    101/39/9     80.9/19.1   128    96/26/6      85.2/14.8   **0.026**     7   ([@b23-mmr-16-02-1927])
  Pan, 2014               China              Asian       Gastric cancer               308    39/69/200    23.9/76.1   307    9/100/198    19.2/80.8   0.390         7   ([@b15-mmr-16-02-1927])
  Purdue, 2007            USA                Mixed       Testicular germ cell tumor   506    363/133/10   84.9/15.1   606    450/143/13   86.1/13.9   0.680         8   ([@b40-mmr-16-02-1927])
  Saxena, 2014            India              Caucasian   Hepatocellular carcinoma     59     16/40/3      61.0/39.0   153    58/88/7      66.7/33.3   **\<0.001**   7   ([@b32-mmr-16-02-1927])
  Schonfeld, 2010         USA                Mixed       Breast cancer                838    616/206/16   85.8/14.2   1074   750/289/35   83.3/16.7   0.273         8   ([@b21-mmr-16-02-1927])
  Suchy, 2008             Poland             Caucasian   Colorectal cancer            350    225/113/12   80.4/19.6   350    230/107/13   81.0/19.0   0.899         8   ([@b36-mmr-16-02-1927])
  Tsai, 2005              Taiwan             Asian       Oral carcinoma               130    9/21/100     15.0/85.0   105    2/28/75      15.2/84.8   0.741         7   ([@b29-mmr-16-02-1927])
  Vairaktaris, 2008       Greek and German   Caucasian   Oral carcinoma               156    84/46/26     68.6/31.4   162    99/48/15     75.9/24.1   **0.016**     7   ([@b30-mmr-16-02-1927])
  Welsh, 2011             UK                 Caucasian   Skin cancer                  892    675/197/20   86.6/13.3   801    608/174/19   86.8/13.2   0.126         8   ([@b24-mmr-16-02-1927])
  Wiemels, 2007           USA                Mixed       Glioma                       384    278/95/11    84.8/15.2   468    313/144/11   82.3/17.7   0.239         8   ([@b39-mmr-16-02-1927])
  Wilkening, 2008         North Sweden       Caucasian   Colorectal cancer            304    183/104/17   77.3/22.7   582    339/200/43   75.4/24.6   0.079         8   ([@b37-mmr-16-02-1927])
  Yang, 2014              Taiwan             Asian       Oral carcinoma               463    13/148/302   18.8/81.2   623    23/218/382   21.2/78.8   0.233         7   ([@b53-mmr-16-02-1927])
  Yang, 2014              Taiwan             Asian       Pharyngeal carcinoma         129    4/43/82      19.8/80.2   623    23/218/382   21.2/78.8   0.233         7   ([@b53-mmr-16-02-1927])
  Yannopoulos, 2007       Greece             Caucasian   Colorectal cancer            93     73/15/5      86.6/13.4   108    69/30/9      77.8/22.2   **0.041**     7   ([@b38-mmr-16-02-1927])
  Zambon, 2008            Italy              Caucasian   Gastric cancer               40     32/7/1       88.8/11.2   64     45/17/2      83.6/16.4   0.800         7   ([@b16-mmr-16-02-1927])

Significant associations are denoted in bold font. HWE, Hardy-Weinberg equilibrium; NOS, Newcastle-Ottawa quality assessment scale.

###### 

Subgroup analyses for interleukin-4 rs2243250 polymorphism and cancer risk.

  A, Gastric cancer (n=6^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                      
  -------------------------------------------------------------------------------- ------------ ------------------------ ----- ---------
  CC vs. CT                                                                        0.47         1.24 (0.69--2.20)        78%   0.0003
  CT vs. TT                                                                        **0.004**    **0.75 (0.61--0.91)**    0%    0.85
  TT vs. CC                                                                        0.57         0.81 (0.40--1.66)        63%   0.02
  CC vs. CT + TT                                                                   0.11         1.42 (0.92--2.20)        68%   0.007
  CT vs. CC + TT                                                                   **0.002**    **0.77 (0.66--0.91)**    0%    0.62
  TT vs. CC + CT                                                                   0.63         1.06 (0.85--1.32)        0%    0.95
  C vs. T                                                                          **0.04**     **1.15 (1.01--1.32)**    21%   0.28
                                                                                                                               
  B, Oral carcinoma (n=3^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                      
                                                                                                                               
  CC vs. CT                                                                        0.43         1.41 (0.60--3.30)        45%   0.14
  CT vs. TT                                                                        0.68         0.84 (0.37--1.91)        80%   0.007
  TT vs. CC                                                                        0.67         0.78 (0.25--2.44)        77%   0.01
  CC vs. CT + TT                                                                   0.45         0.41 (0.58--3.47)        70%   0.04
  CT vs. CC + TT                                                                   0.90         0.96 (0.54--1.71)        70%   0.03
  TT vs. CC + CT                                                                   0.83         1.09 (0.50--2.39)        82%   0.004
  C vs. T                                                                          0.88         1.05 (0.60--1.84)        82%   0.004
                                                                                                                               
  C, Colorectal cancer (n=3^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                   
                                                                                                                               
  CC vs. TT                                                                        0.51         1.12 (0.80--1.57)        55%   0.11
  CT vs. TT                                                                        0.43         1.20 (0.76--1.90)        0%    0.86
  TT vs. CC                                                                        0.83         1.04 (0.70--1.55)        0%    0.41
  CC vs. CT + TT                                                                   0.39         1.16 (0.83--1.62)        58%   0.09
  CT vs. CC + TT                                                                   0.74         0.97 (0.79--1.19)        50%   0.14
  TT vs. CC + CT                                                                   0.23         0.77 (0.50--1.19)        0%    0.84
  C vs. T                                                                          0.31         1.15 (0.88--1.52)        56%   0.10
                                                                                                                               
  D, Lung cancer (n=3^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                         
                                                                                                                               
  CC vs. CT                                                                        0.97         0.99 (0.67--1.47)        63%   0.07
  CT vs. TT                                                                        0.19         0.85 (0.67--1.08)        54%   0.14
  TT vs. CC                                                                        0.75         0.87 (0.35--2.17)        89%   0.00001
  CC vs. CT + TT                                                                   0.89         1.05 (0.54--2.01)        88%   0.0002
  CT vs. CC + TT                                                                   **0.02**     **0.84 (0.75--0.97)**    0%    0.58
  TT vs. CC + CT                                                                   0.86         0.96 (0.62--1.49)        85%   0.001
  C vs. T                                                                          0.92         1.02 (0.68--1.54)        92%   0.00001
                                                                                                                               
  E, Skin cancer (n=2^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                         
                                                                                                                               
  CC vs. CT                                                                        0.59         1.06 (0.86--1.31)        0%    0.39
  CT vs. TT                                                                        0.84         1.07 (0.57--2.00)        23%   0.25
  TT vs. CC                                                                        0.72         0.89 (0.49--1.64)        44%   0.18
  CC vs. CT + TT                                                                   0.53         1.07 (0.87--1.31)        33%   0.22
  CT vs. CC + TT                                                                   0.60         0.94 (0.76--1.17)        0%    0.43
  TT vs. CC + CT                                                                   0.74         0.90 (0.49--1.65)        41%   0.19
  C vs. T                                                                          0.45         1.17 (0.77--1.77)        59%   0.12
                                                                                                                               
  F, Hepatocellular cancer (n=2^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                               
                                                                                                                               
  CC vs. CT                                                                        0.37         0.23 (0.01--5.69)        92%   0.0005
  CT vs. TT                                                                        0.62         0.88 (0.54--1.44)        0%    0.79
  TT vs. CC                                                                        0.93         1.05 (0.36--3.04)        10%   0.33
  CC vs. CT + TT                                                                   0.46         0.51 (0.09--3.03)        80%   0.03
  CT vs. CC + TT                                                                   0.16         0.55 (0.23--1.27)        84%   0.01
  TT vs. CC + CT                                                                   0.95         0.99 (0.62--1.58)        36%   0.21
  C vs. T                                                                          0.28         0.48 (0.13--1.80)        96%   0.00001
                                                                                                                               
  G, Lymphoma (n=2^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                            
                                                                                                                               
  CC vs. CT                                                                        0.42         0.82 (0.50--1.34)        0%    0.59
  CT vs. TT                                                                        0.28         1.85 (0.61--5.61)        0%    0.32
  TT vs. CC                                                                        0.34         0.60 (0.21--1.72)        24%   0.25
  CC vs. CT + TT                                                                   0.81         0.95 (0.59--1.51)        0%    0.43
  CT vs. CC + TT                                                                   0.45         1.21 (0.74--1.98)        0%    0.88
  TT vs. CC + CT                                                                   0.31         0.58 (0.21--1.65)        23%   0.26
  C vs. T                                                                          0.88         0.95 (0.51--1.76)        54%   0.14
                                                                                                                               
  H, Prostate cancer (n=2^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                     
                                                                                                                               
  CC vs. CT                                                                        0.87         1.07 (0.48--2.41)        78%   0.03
  CT vs. TT                                                                        **0.004**    **1.48 (1.14--1.92)**    0%    0.43
  TT vs. CC                                                                        **0.0009**   **0.48 (0.31--0.74)**    0%    0.43
  CC vs. CT + TT                                                                   0.52         1.31 (0.57--3.01)        82%   0.02
  CT vs. CC + TT                                                                   **0.02**     **1.33 (1.05--1.69)**    0%    0.66
  TT vs. CC + CT                                                                   **0.0004**   **0.64 (0.50--0.82)**    0%    0.90
  C vs. T                                                                          0.20         1.29 (0.87--1.90)        66%   0.09
                                                                                                                               
  I, Breast cancer (n=2^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                       
                                                                                                                               
  CC vs. CT                                                                        **0.05**     **1.21 (1.00--1.46)**    21%   0.26
  CT vs. TT                                                                        0.18         1.46 (0.84--2.54)        0%    0.61
  TT vs. CC                                                                        **0.04**     **0.56 (0.33--0.97)**    0%    0.91
  CC vs. CT + TT                                                                   **0.02**     **1.25 (1.04--1.51)**    7%    0.30
  CT vs. CC + TT                                                                   0.07         0.84 (0.70--1.02)        21%   0.26
  TT vs. CC + CT                                                                   0.06         0.60 (0.35--1.02)        0%    0.82
  C vs. T                                                                          **0.007**    **1.25 (1.06--1.47)**    0%    0.41
                                                                                                                               
  J, Bladder cancer (n=1^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                      
                                                                                                                               
  CC vs. CT                                                                        0.32         1.26 (0.80--1.99)        NA    NA
  CT vs. TT                                                                        0.38         0.92 (0.76--1.11)        NA    NA
  TT vs. CC                                                                        0.51         0.86 (0.56--1.34)        NA    NA
  CC vs. CT + TT                                                                   0.43         1.19 (0.77--1.85)        NA    NA
  CT vs. CC + TT                                                                   0.33         0.91 (0.75--1.10)        NA    NA
  TT vs. CC + CT                                                                   0.54         1.06 (0.88--1.28)        NA    NA
  C vs. T                                                                          0.81         0.98 (0.84--1.15)        NA    NA
                                                                                                                               
  K, Brain tumor (n=1^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                         
                                                                                                                               
  CC vs. CT                                                                        0.06         1.35 (0.99--1.83)        NA    NA
  CT vs. TT                                                                        0.35         0.66 (0.28--1.58)        NA    NA
  TT vs. CC                                                                        0.20         1.76 (0.75--4.14)        NA    NA
  CC vs. CT + TT                                                                   0.08         1.30 (0.97--1.74)        NA    NA
  CT vs. CC + TT                                                                   0.05         0.74 (0.55--1.00)        NA    NA
  TT vs. CC + CT                                                                   0.64         1.23 (0.53--2.86)        NA    NA
  C vs. T                                                                          0.17         1.20 (0.93--1.55)        NA    NA
                                                                                                                               
  L, Testicular tumor (n=1^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                    
                                                                                                                               
  CC vs. CT                                                                        0.31         0.87 (0.66--1.14)        NA    NA
  CT vs. TT                                                                        0.66         1.21 (0.51--2.85)        NA    NA
  TT vs. CC                                                                        0.91         0.95 (0.41--2.20)        NA    NA
  CC vs. CT + TT                                                                   0.35         0.88 (0.67--1.15)        NA    NA
  CT vs. CC + TT                                                                   0.30         1.15 (0.88--1.52)        NA    NA
  TT vs. CC + CT                                                                   0.84         0.92 (0.40--2.12)        NA    NA
  C vs. T                                                                          0.43         0.91 (0.72--1.15)        NA    NA
                                                                                                                               
  M, Leukemia (n=1^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                            
                                                                                                                               
  CC vs. CT                                                                        **0.005**    **5.35 (1.64--17.47)**   NA    NA
  CT vs. TT                                                                        NA           NA                       NA    NA
  TT vs. CC                                                                        NA           NA                       NA    NA
  CC vs. CT + TT                                                                   **0.01**     **4.67 (1.42--15.31)**   NA    NA
  CT vs. CC + TT                                                                   **0.005**    **0.19 (0.06--0.61)**    NA    NA
  TT vs. CC + CT                                                                   NA           1.11 (0.86--1.44)        NA    NA
  C vs. T                                                                          0.06         1.97 (0.96--4.02)        NA    NA
                                                                                                                               
  N, Renal cell carcinoma (n=1^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                
                                                                                                                               
  CC vs. CT                                                                        0.11         0.63 (0.36--1.11)        NA    NA
  CT vs. TT                                                                        0.55         0.93 (0.73--1.18)        NA    NA
  TT vs. CC                                                                        0.06         1.71 (0.99--2.95)        NA    NA
  CC vs. CT + TT                                                                   0.06         0.60 (0.35--1.03)        NA    NA
  CT vs. CC + TT                                                                   0.76         0.96 (0.76--1.22)        NA    NA
  TT vs. CC + CT                                                                   0.26         1.14 (0.91--1.44)        NA    NA
  C vs. T                                                                          0.10         0.85 (0.70--1.03)        NA    NA
                                                                                                                               
  O, Caucasian (n=15^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                          
                                                                                                                               
  CC vs. CT                                                                        0.85         0.98 (0.75--1.27)        81%   0.00001
  CT vs. TT                                                                        **0.03**     **0.82 (0.68--0.98)**    46%   0.03
  TT vs. CC                                                                        0.84         1.03 (0.81--1.30)        0%    0.50
  CC vs. CT + TT                                                                   0.56         1.07 (0.85--1.34)        77%   0.00001
  CT vs. CC + TT                                                                   **0.02**     **0.79 (0.66--0.96)**    64%   0.0003
  TT vs. CC + CT                                                                   0.10         0.83 (0.67--1.04)        4%    0.41
  C vs. T                                                                          0.84         1.03 (0.80--1.33)        90%   0.00001
                                                                                                                               
  P, Asian (n=12^[a](#tfn2-mmr-16-02-1927){ref-type="table-fn"}^)                                                              
                                                                                                                               
  CC vs. CT                                                                        0.26         1.22 (0.87--1.72)        71%   0.00001
  CT vs. TT                                                                        0.11         0.90 (0.79--1.02)        47%   0.04
  TT vs. CC                                                                        0.38         0.83 (0.54--1.27)        80%   0.00001
  CC vs. CT + TT                                                                   0.34         1.19 (0.83--1.72)        77%   0.00001
  CT vs. CC + TT                                                                   **0.006**    **0.89 (0.82--0.97)**    36%   0.11
  TT vs. CC + CT                                                                   0.62         1.04 (0.89--1.21)        66%   0.0007
  C vs. T                                                                          0.90         1.01 (0.87--1.18)        80%   0.00001

Number of articles. Significant associations are denoted in bold font. OR, odds ratio; CI, confidence interval; NA, not applicable.

###### 

Characteristics of subjects included in the meta-analysis of inteleukin-4 rs2070874 polymorphism and cancer risk.

                                                                            Case   Control                                                              
  ------------------ ------------- ----------- ---------------------------- ------ ------------ ----------- ------ ------------ ----------- ------- --- -------------------------
  Amirzargar, 2005   Iran          Caucasian   Leukemia                     30     20/5/5       75.0/25.0   40     22/18/0      77.5/22.5   0.066   7   ([@b42-mmr-16-02-1927])
  Chang, 2015        Taiwan        Asian       Lung cancer                  358    238/101/19   80.6/19.4   716    453/223/40   78.8/21.2   0.075   7   ([@b35-mmr-16-02-1927])
  Crusius, 2008      Netherlands   Caucasian   Gastric cancer               243    159/77/7     81.3/18.7   1160   839/296/25   85.1/14.9   0.853   8   ([@b11-mmr-16-02-1927])
  Gaur, 2011         India         Caucasian   Oral carcinoma               140    20/61/59     36.1/63.9   120    11/38/71     25.0/75.0   0.088   8   ([@b28-mmr-16-02-1927])
  Gu, 2008           USA           Mixed       Skin cancer                  217    160/52/5     85.7/14.3   214    165/43/6     87.1/12.9   0.132   8   ([@b45-mmr-16-02-1927])
  Lu, 2010           China         Asian       Gastric cancer               1042   27/271/744   15.6/84.4   1099   24/332/743   17.3/82.7   0.062   7   ([@b44-mmr-16-02-1927])
  Lu, 2014           China         Asian       Hepatocellular cancer        135    8/43/84      21.9/78.1   147    4/45/98      18.0/82.0   0.664   7   ([@b31-mmr-16-02-1927])
  Purdue, 2007       USA           Mixed       Testicular germ cell tumor   501    364/128/9    85.4/14.6   598    447/139/12   86.4/13.6   0.757   8   ([@b40-mmr-16-02-1927])
  Schonfeld, 2010    USA           Mixed       Breast cancer                818    600/206/12   85.9/14.1   1081   763/288/30   83.9/16.1   0.654   7   ([@b21-mmr-16-02-1927])
  Shamran, 2014      Iraq          Caucasian   Brain tumor                  100    71/26/3      84.0/16.0   40     22/13/5      71.3/28.7   0.191   8   ([@b43-mmr-16-02-1927])
  Wiemels, 2007      USA           Mixed       Brain tumor                  386    281/93/12    84.8/15.2   471    328/134/9    83.9/16.1   0.267   8   ([@b39-mmr-16-02-1927])

Significant associations are denoted in bold font. HWE, Hardy-Weinberg equilibrium; NOS, Newcastle-Ottawa quality assessment scale.

###### 

Subgroup analyses for interleukin-4 rs2070874polymorphism and cancer risk.

  A, Gastric cancer (n=3^[a](#tfn4-mmr-16-02-1927){ref-type="table-fn"}^)                                                
  --------------------------------------------------------------------------- ----------- ------------------------ ----- --------
  CC vs. CT                                                                   0.91        1.03 (0.60--1.76)        59%   0.09
  CT vs. TT                                                                   0.07        0.85 (0.71--1.01)        0%    0.52
  TT vs. CC                                                                   0.67        0.91 (0.59--1.41)        25%   0.26
  CC vs. CT + TT                                                              0.94        1.02 (0.60--1.74)        60%   0.08
  CT vs. CC + TT                                                              0.85        1.04 (0.72--1.49)        75%   0.85
  TT vs. CC + CT                                                              0.11        1.15 (0.97--1.36)        5%    0.35
  C vs. T                                                                     0.35        0.90 (0.72--1.12)        53%   0.12
                                                                                                                         
  B, Brain tumor (n=2^[a](#tfn4-mmr-16-02-1927){ref-type="table-fn"}^)                                                   
                                                                                                                         
  CC vs. CT                                                                   0.10        1.27 (0.95--1.70)        0%    0.55
  CT vs. TT                                                                   0.86        1.17 (0.19--7.13)        75%   0.05
  TT vs. CC                                                                   0.62        0.59 (0.07--4.70)        82%   0.02
  CC vs. CT + TT                                                              0.11        1.25 (0.95--1.65)        41%   0.19
  CT vs. CC + TT                                                              0.30        0.52 (0.15--1.77)        78%   0.03
  TT vs. CC + CT                                                              0.67        0.65 (0.09--4.74)        81%   0.02
  C vs. T                                                                     0.29        1.42 (0.74--2.73)        75%   0.05
                                                                                                                         
  C, Leukemia (n=1^[a](#tfn4-mmr-16-02-1927){ref-type="table-fn"}^)                                                      
                                                                                                                         
  CC vs. CT                                                                   **0.05**    **3.27 (1.02--10.45)**   NA    NA
  CT vs. TT                                                                   **0.02**    **0.03 (0.00--0.57)**    NA    NA
  TT vs. CC                                                                   0.10        12.07 (0.63--232.12)     NA    NA
  CC vs. CT + TT                                                              0.33        1.64 (0.61--4.37)        NA    NA
  CT vs. CC + TT                                                              **0.02**    **0.24 (0.08--0.77)**    NA    NA
  TT vs. CC + CT                                                              0.06        17.47 (0.93--329.53)     NA    NA
  C vs. T                                                                     0.73        0.87 (0.40--1.91)        NA    NA
                                                                                                                         
  D, Lung cancer (n=1^[a](#tfn4-mmr-16-02-1927){ref-type="table-fn"}^)                                                   
                                                                                                                         
  CC vs. CT                                                                   0.30        1.16 (0.87--1.54)        NA    NA
  CT vs. TT                                                                   0.88        0.95 (0.53--1.73)        NA    NA
  TT vs. CC                                                                   0.73        0.90 (0.51--1.60)        NA    NA
  CC vs. CT + TT                                                              0.30        1.15 (0.88--1.50)        NA    NA
  CT vs. CC + TT                                                              0.32        0.87 (0.66--1.15)        NA    NA
  TT vs. CC + CT                                                              0.85        0.95 (0.54--1.66)        NA    NA
  C vs. T                                                                     0.35        1.11 (0.89--1.39)        NA    NA
                                                                                                                         
  E, Oral carcinoma (n=1^[a](#tfn4-mmr-16-02-1927){ref-type="table-fn"}^)                                                
                                                                                                                         
  CC vs. CT                                                                   0.77        1.13 (0.49--2.62)        NA    NA
  CT vs. TT                                                                   **0.02**    **1.93 (1.13--3.29)**    NA    NA
  TT vs. CC                                                                   0.06        0.46 (0.20--1.03)        NA    NA
  CC vs. CT + TT                                                              0.21        1.65 (0.76--3.60)        NA    NA
  CT vs. CC + TT                                                              **0.05**    **1.67 (1.00--2.77)**    NA    NA
  TT vs. CC + CT                                                              **0.006**   **0.50 (0.31--0.82)**    NA    NA
  C vs. T                                                                     **0.007**   **1.69 (1.16--2.48)**    NA    NA
                                                                                                                         
  F, Breast cancer (n=1^[a](#tfn4-mmr-16-02-1927){ref-type="table-fn"}^)                                                 
                                                                                                                         
  CC vs. CT                                                                   0.37        1.10 (0.89--1.35)        NA    NA
  CT vs. TT                                                                   0.10        1.79 (0.89--3.58)        NA    NA
  TT vs. CC                                                                   0.05        0.51 (0.26--1.00)        NA    NA
  CC vs. CT + TT                                                              0.18        1.15 (0.94--1.41)        NA    NA
  CT vs. CC + TT                                                              0.47        0.93 (0.75--1.14)        NA    NA
  TT vs. CC + CT                                                              0.06        0.52 (0.27--1.03)        NA    NA
  C vs. T                                                                     0.08        1.17 (0.98--1.40)        NA    NA
                                                                                                                         
  G, Testicular tumor (n=1^[a](#tfn4-mmr-16-02-1927){ref-type="table-fn"}^)                                              
                                                                                                                         
  CC vs. CT                                                                   0.38        0.88 (0.67--1.17)        NA    NA
  CT vs. TT                                                                   0.65        1.23 (0.50--3.01)        NA    NA
  TT vs. CC                                                                   0.85        0.92 (0.38--2.21)        NA    NA
  CC vs. CT + TT                                                              0.43        0.90 (0.69--1.18)        NA    NA
  CT vs. CC + TT                                                              0.38        1.13 (0.86--1.49)        NA    NA
  TT vs. CC + CT                                                              0.80        0.89 (0.37--2.14)        NA    NA
  C vs. T                                                                     0.53        0.93 (0.73--1.18)        NA    NA
                                                                                                                         
  H, Skin cancer (n=1^[a](#tfn4-mmr-16-02-1927){ref-type="table-fn"}^)                                                   
                                                                                                                         
  CC vs. CT                                                                   0.35        0.80 (0.51--1.27)        NA    NA
  CT vs. TT                                                                   0.56        1.45 (0.41--5.08)        NA    NA
  TT vs. CC                                                                   0.81        0.86 (0.26--2.87)        NA    NA
  CC vs. CT + TT                                                              0.42        0.83 (0.54--1.29)        NA    NA
  CT vs. CC + TT                                                              0.33        1.25 (0.79--1.98)        NA    NA
  TT vs. CC + CT                                                              0.74        0.82 (0.25--2.72)        NA    NA
  C vs. T                                                                     0.54        0.88 (0.60--1.31)        NA    NA
                                                                                                                         
  I, Caucasian (n=4^[a](#tfn4-mmr-16-02-1927){ref-type="table-fn"}^)                                                     
                                                                                                                         
  CC vs. CT                                                                   0.48        1.25 (0.67--2.33)        66%   0.03
  CT vs. TT                                                                   0.78        1.16 (0.41--3.29)        70%   0.02
  TT vs. CC                                                                   0.67        0.78 (0.24--2.51)        72%   0.01
  CC vs. CT + TT                                                              0.40        1.30 (0.71--2.38)        70%   0.02
  CT vs. CC + TT                                                              0.92        0.97 (0.55--1.73)        73%   0.01
  TT vs. CC + CT                                                              0.68        0.80 (0.28--2.27)        73%   0.01
  C vs. T                                                                     0.45        1.23 (0.71--2.13)        83%   0.0006
                                                                                                                         
  J, Asian (n=3^[a](#tfn4-mmr-16-02-1927){ref-type="table-fn"}^)                                                         
                                                                                                                         
  CC vs. CT                                                                   0.12        1.22 (0.95--1.56)        0%    0.77
  CT vs. TT                                                                   0.07        0.86 (0.72--1.01)        0%    0.49
  TT vs. CC                                                                   0.35        0.83 (0.57--1.22)        0%    0.54
  CC vs. CT + TT                                                              0.15        1.19 (0.94--1.51)        0%    0.58
  CT vs. CC + TT                                                              **0.03**    **0.85 (0.73--0.98)**    0%    0.61
  TT vs. CC + CT                                                              0.17        1.12 (0.95--1.32)        15%   0.17
  C vs. T                                                                     0.81        1.03 (0.83--1.26)        54%   0.11

Number of articles. Significant associations are denoted in bold font. OR, odds ratio; CI, confidence interval; NA, not applicable.

###### 

Characteristics of subjects included in the meta-analysis of interleukin-4 rs79071878 polymorphism and cancer risk.

                                                                Case   Control                                                                
  ----------------- -------- ----------- ---------------------- ------ ----------- ----------- ----- ------------ ----------- ----------- --- -------------------------
  Bozdoğan, 2015    Turkey   Caucasian   Bladder cancer         100    9/29/62     40.0/60.0   102   0/23/79      38.7/61.3   0.199       7   ([@b48-mmr-16-02-1927])
  Chen, 2006        China    Asian       Gastric cancer         151    100/45/6    81.1/18.9   107   81/23/3      86.4/13.6   0.393       7   ([@b46-mmr-16-02-1927])
  Hsieh, 2007       Taiwan   Asian       Leiomyoma              162    105/53/4    81.2/18.8   156   108/42/6     82.7/17.3   0.458       8   ([@b27-mmr-16-02-1927])
  Kesarwani, 2008   India    Caucasian   Prostate cancer        200    126/69/5    80.3/19.7   202   130/62/10    79.7/20.3   0.465       8   ([@b52-mmr-16-02-1927])
  Konwar, 2009      India    Caucasian   Breast cancer          100    10/37/53    28.5/71.5   200   18/53/129    22.3/77.7   **0.001**   7   ([@b51-mmr-16-02-1927])
  Lai, 2005         Taiwan   Asian       Gastric cancer         123    82/38/3     82.1/17.9   103   66/33/4      80.1/19.9   0.961       7   ([@b14-mmr-16-02-1927])
  Shekari, 2012     India    Caucasian   Cervical cancer        200    9/66/125    21.0/79.0   200   11/63/126    21.3/78.7   0.405       8   ([@b50-mmr-16-02-1927])
  Tsai, 2005        Taiwan   Asian       Bladder cancer         138    119/18/1    92.8/7.2    105   67/33/5      79.5/20.5   0.720       7   ([@b47-mmr-16-02-1927])
  Tsai, 2005        Taiwan   Asian       Oral carcinoma         121    97/30/3     88.8/11.2   105   67/33/5      47.7/52.3   0.720       7   ([@b29-mmr-16-02-1927])
  Yang, 2014        Taiwan   Asian       Oral carcinoma         463    309/145/9   82.4/17.6   623   398/207/18   80.5/19.5   0.146       8   ([@b53-mmr-16-02-1927])
  Yang, 2014        Taiwan   Asian       Pharyngeal carcinoma   129    87/39/3     82.6/17.4   623   398/207/18   80.5/19.5   0.146       8   ([@b53-mmr-16-02-1927])

Significant associations are denoted in bold font. Alleles of two and three repeats were designated as RP1 and RP2, respectively. Genotypes were designated as RP1.1=RP1/RP1, RP1.2=RP1/RP2 and RP2.2=RP2/RP2. RP, repeat; HWE, Hardy-Weinberg equilibrium; NOS, Newcastle-Ottawa quality assessment scale.

###### 

Subgroup analyses for inteleukin-4 rs79071878polymorphism and cancer risk.

  A, Bladder cancer (n=2^[a](#tfn6-mmr-16-02-1927){ref-type="table-fn"}^)                                                       
  -------------------------------------------------------------------------- ----------- ----------------------- -------------- -------------------------------
  RP1.1 vs. RP1.2                                                            0.56        1.09 (0.81--1.46)       8%             0.30
  RP1.2 vs. RP2.2                                                            **0.008**   **1.40 (1.09--1.79)**   0%             0.65
  RP2.2 vs. RP1.1                                                            **0.006**   **0.62 (0.44--0.87)**   0%             0.57
  RP1.1 vs. RP1.2/ RP2.2                                                     0.30        1.17 (0.87--1.58)       35%            0.21
  RP1.2 vs. RP1.1/RP2.2                                                      0.83        1.03 (0.81--1.13)       90%            0.002
  RP2.2 vs. RP1.1/ RP1.2                                                     **0.002**   **0.69 (0.55--0.88)**   6%             0.30
  RP1 vs. RP2                                                                **0.005**   **1.26 (1.00--1.58)**   0%             0.44
                                                                                                                                
  B, Gastric cancer (n=2^[a](#tfn6-mmr-16-02-1927){ref-type="table-fn"}^)                                                       
                                                                                                                                
  RP1.1 vs. RP1.2                                                            0.36        0.83 (0.49--1.40)       40%            0.20
  RP1.2 vs. RP2.2                                                            0.73        1.21 (0.42--3.50)       0%             0.68
  RP2.2 vs. RP1.1                                                            0.94        1.04 (0.38--2.85)       0%             0.35
  RP1.1 vs. RP1.2/RP2.2                                                      0.55        0.84 (0.48--1.48)       52%            0.15
  RP1.2 vs. RP1.1/RP2.2                                                      0.35        1.21 (0.81--1.81)       30%            0.23
  RP2.2 vs. RP1.1/RP1.2                                                      0.97        0.98 (0.36--2.69)       0%             0.43
  RP1 vs. RP2                                                                0.63        0.88 (0.52--1.47)       57%            0.13
                                                                                                                                
  C, Leiomyoma (n=1^[a](#tfn6-mmr-16-02-1927){ref-type="table-fn"}^)                                                            
                                                                                                                                
  RP1.1 vs. RP1.2                                                            0.29        0.77 (0.47--1.25)       NA             NA
  RP1.2 vs. RP2.2                                                            0.35        1.89 (0.50--7.15)       NA             NA
  RP2.2 vs. RP1.1                                                            0.57        0.69 (0.19--2.50)       NA             NA
  RP1.1 vs. RP1.2/RP2.2                                                      0.40        0.82 (0.51--1.31)       NA             NA
  RP1.2 vs. RP1.1/RP2.2                                                      0.26        1.32 (0.81--2.14)       NA             NA
  RP2.2 vs. RP1.1/RP1.2                                                      0.49        0.63 (0.18--2.29)       NA             NA
  RP1 vs. RP2                                                                0.62        0.90 (0.60--1.35)       NA             NA
                                                                                                                                
  D, Oral carcinoma (n=1^[a](#tfn6-mmr-16-02-1927){ref-type="table-fn"}^)                                                       
                                                                                                                                
  RP1.1 vs. RP1.2                                                            0.12        1.59 (0.89--2.86)       NA             NA
  RP1.2 vs. RP2.2                                                            0.59        1.52 (0.33--6.89)       NA             NA
  RP2.2 vs. RP1.1                                                            0.24        0.41 (0.10--1.79)       NA             NA
  RP1.1 vs. RP1.2/RP2.2                                                      0.07        1.67 (0.95--2.92)       NA             NA
  RP1.2 vs. RP1.1/RP2.2                                                      0.15        0.65 (0.37--1.17)       NA             NA
  RP2.2 vs. RP1.1/RP1.2                                                      0.36        0.51 (0.12--2.18)       NA             NA
  RP1 vs. RP2                                                                0.06        1.60 (0.99--2.60)       NA             NA
                                                                                                                                
  E, Prostate cancer (n=1^[a](#tfn6-mmr-16-02-1927){ref-type="table-fn"}^)                                                      
                                                                                                                                
  RP1.1 vs. RP1.2                                                            0.52        0.87 (0.57--1.33)       NA             NA
  RP1.2 vs. RP2.2                                                            0.16        2.23 (0.72--6.87)       NA             NA
  RP2.2 vs. RP1.1                                                            0.24        0.52 (0.17--1.55)       NA             NA
  RP1.1 vs. RP1.2/RP2.2                                                      0.78        0.94 (0.63--1.42)       NA             NA
  RP1.2 vs. RP1.1/RP2.2                                                      0.42        1.19 (0.78--1.81)       NA             NA
  RP2.2 vs. RP1.1/RP1.2                                                      0.20        0.49 (0.17--1.47)       NA             NA
  RP1 vs. RP2                                                                0.85        1.03 (0.73--1.46)       NA             NA
                                                                                                                                
  F, Cervical cancer (n=1^[a](#tfn6-mmr-16-02-1927){ref-type="table-fn"}^)                                                      
                                                                                                                                
  Variable                                                                   P-value     OR (95% Cl)             I-square (%)   P-value for the heterogeneity
  RP1.1 vs. RP1.2                                                            0.61        0.78 (0.30--2.01)       NA             NA
  RP1.2 vs. RP2.2                                                            0.80        1.06 (0.69--1.61)       NA             NA
  RP2.2 vs. RP1.1                                                            0.68        1.21 (0.49--3.03)       NA             NA
  RP1.1 vs. RP1.2/RP2.2                                                      0.65        0.81 (0.33--2.00)       NA             NA
  RP1.2 vs. RP1.1/RP2.2                                                      0.75        1.07 (0.70--1.63)       NA             NA
  RP2.2 vs. RP1.1/RP1.2                                                      0.92        0.98 (0.65--1.47)       NA             NA
  RP1 vs. RP2                                                                0.93        0.99 (0.70--1.38)       NA             NA
                                                                                                                                
  G, Breast cancer (n=1^[a](#tfn6-mmr-16-02-1927){ref-type="table-fn"}^)                                                        
                                                                                                                                
  RP1.1 vs. RP1.2                                                            0.61        0.80 (0.33--1.92)       NA             NA
  RP1.2 vs. RP2.2                                                            **0.05**    **1.70 (1.00--2.88)**   NA             NA
  RP2.2 vs. RP1.1                                                            0.48        0.74 (0.32--1.71)       NA             NA
  RP1.1 vs. RP1.2/RP2.2                                                      0.78        1.12 (0.50--2.53)       NA             NA
  RP1.2 vs. RP1.1/RP2.2                                                      0.06        1.63 (0.98--2.72)       NA             NA
  RP2.2 vs. RP1.1/RP1.2                                                      0.06        0.62 (038--1.01)        NA             NA
  RP1 vs. RP2                                                                0.09        1.39 (0.95--2.05)       NA             NA
                                                                                                                                
  H, Caucasian (n=4^[a](#tfn6-mmr-16-02-1927){ref-type="table-fn"}^)                                                            
                                                                                                                                
  RP1.1 vs. RP1.2                                                            0.74        0.94 (0.67--1.33)       24%            0.26
  RP1.2 vs. RP2.2                                                            **0.03**    **1.38 (1.04--1.83)**   1%             0.39
  RP2.2 vs. RP1.1                                                            0.05        0.61 (0.37--1.01)       49%            0.12
  RP1.1 vs. RP1.2/RP2.2                                                      0.64        1.08 (0.78--1.50)       40%            0.17
  RP1.2 vs. RP1.1/RP2.2                                                      0.06        1.26 (0.99--1.59)       0%             0.63
  RP2.2 vs. RP1.1/RP1.2                                                      **0.01**    **0.71 (0.54--0.93)**   37%            0.19
  RP1 vs. RP2                                                                0.13        1.30 (0.92--1.82)       66%            0.03
                                                                                                                                
  I, Asian (n=6^[a](#tfn6-mmr-16-02-1927){ref-type="table-fn"}^)                                                                
                                                                                                                                
  RP1.1 vs. RP1.2                                                            0.41        1.17 (0.81--1.71)       72%            0.003
  RP1.2 vs. RP2.2                                                            0.14        1.46 (0.88--2.42)       0%             0.98
  RP2.2 vs. RP1.1                                                            0.05        0.62 (0.38--1.01)       0%             0.48
  RP1.1 vs. RP1.2/RP2.2                                                      0.31        1.22 (0.83--1.81)       76%            0.0009
  RP1.2 vs. RP1.2/RP2.2                                                      0.46        0.87 (0.61--1.25)       70%            0.006
  RP2.2 vs. RP1.1/RP1.2                                                      0.07        0.64 (0.40--1.04)       0%             0.67
  RP1 vs. RP2                                                                0.23        1.23 (0.88--1.74)       76%            0.0008

Number of articles. Significant associations are denoted in bold font. Alleles of two and three repeats were designated as RP1 and RP2, respectively. Genotypes were designated as RP1.1=RP1/RP1, RP1.2=RP1/RP2 and RP2.2=RP2/RP2. RP, repeat; OR, odds ratio; CI, confidence interval; NA, not applicable.
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